Advertisement

A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes

  • Régis Bouquié
  • Annabelle Bonnin
  • Karine Bernardeau
  • Amir Khammari
  • Brigitte Dréno
  • Francine Jotereau
  • Nathalie Labarrière
  • François Lang
Original Article

Abstract

HLA multimers are now widely used to stain and sort CD8 T lymphocytes specific for epitopes from viral or tumoral antigens presented in an HLA class I context. However, the transfer of this technology to a clinical setting to obtain clinical grade CD8 T lymphocytes that may be used in adoptive cell transfer (ACT) is hindered by two main obstacles: the first obstacle is the use of streptavidin or derived products that are not available in clinical grade to multimerize HLA/peptide monomers and the second is the reported high degree of apoptosis that eventually occurs when T cell receptors are crosslinked by HLA multimers. In the present report, we describe new HLA multimers composed of immunomagnetic beads covalently coupled to a mAb specific for the AviTag peptide and coated with HLA/peptide monomers bearing the non biotinylated AviTag at the COOH terminus of the HLA heavy chain. Thus, all the components of this new reagent can be obtained in clinical grade. We compared these new multimers with the previously described multimers made with streptavidin beads coated with biotinylated HLA/peptide monomers, in terms of sorting efficiency, recovery of functional T cells, apoptosis and activation. We provide evidence that the new multimers could very efficiently sort pure populations of T lymphocytes specific for three different melanoma antigens (Melan-A, gp100 and NA17-A) after a single peptide stimulation of melanoma patients’ PBMC. The recovered specific T cells were cytotoxic against the relevant melanoma cell-lines and, in most cases, produced cytokines. In addition, in marked contrast with streptavidin-based multimers, our new multimers induced very little apoptosis or activation after binding specific T lymphocytes. Altogether, these new multimers fulfill all the necessary requirements to select clinical grade T lymphocytes and should facilitate the development of ACT protocols in cancer patients.

Keywords

Immunotherapy Cell-sorting HLA multimers Melanoma T lymphocytes 

Abbreviations

ACT

Adoptive cell therapy

AICD

Activation induced cell death

CMV

Cytomegalovirus

EBV

Epstein–Barr virus

GMP

Good manufacturing practice

CTL

Cytotoxic T lymphocyte

DC

Dendritic cell

HLA

Human leucotyte antigen

PBMC

Peripheral blood mononuclear cells

TCR

T cell receptor

TIL

Tumor inflitrating lymphocyte

Notes

Acknowledgments

This work was supported by a grant from the «Ligue Nationale contre le Cancer» (labellisation 2003–2007) and by a grant from INCa “Thérapie adoptive cellulaire du cancer”.

References

  1. 1.
    Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549–1555PubMedGoogle Scholar
  2. 2.
    Gustafsson A, Levitsky V, Zou JZ , Frisan T, Dalianis T, Ljungman P, Ringden O, Winiarski J, Ernberg I, Masucci MG (2000) Epstein–Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 95:807–814PubMedGoogle Scholar
  3. 3.
    Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, Gee AP, Lin YF, Quiros-Tejeira RE, Reinke P, Schubert S, Gottschalk S, Finegold MJ, Brenner MK, Rooney CM, Heslop HE (2006) Treatment of solid organ transplant recipients with autologous Epstein–Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 108:2942–2949PubMedCrossRefGoogle Scholar
  4. 4.
    Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462–2465PubMedGoogle Scholar
  5. 5.
    Dreno B, Nguyen JM, Khammari A, Pandolfino MC, Tessier MH, Bercegeay S, Cassidanius A, Lemarre P, Billaudel S, Labarriere N, Jotereau F (2002) Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 51:539–546PubMedCrossRefGoogle Scholar
  6. 6.
    Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850–854PubMedCrossRefGoogle Scholar
  7. 7.
    Labarriere N, Pandolfino MC, Gervois N, Khammari A, Tessier MH, Dreno B, Jotereau F (2002) Therapeutic efficacy of melanoma-reactive TIL injected in stage III melanoma patients. Cancer Immunol Immunother 51:532–538PubMedCrossRefGoogle Scholar
  8. 8.
    Guillaume P, Legler DF, Boucheron N, Doucey MA, Cerottini JC, Luescher IF (2003) Soluble major histocompatibility complex-peptide octamers with impaired CD8 binding selectively induce Fas-dependent apoptosis. J Biol Chem 278:4500–4509PubMedCrossRefGoogle Scholar
  9. 9.
    Cebecauer M, Guillaume P, Hozak P, Mark S, Everett H, Schneider P, Luescher IF (2005) Soluble MHC-peptide complexes induce rapid death of CD8 + CTL. J Immunol 174:6809–6819PubMedGoogle Scholar
  10. 10.
    Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, Assenmacher M, Billingham L, Steward C, Crawley C, Olavarria E, Goldman J, Chakraverty R, Mahendra P, Craddock C, Moss PA (2005) Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 202:379–386PubMedCrossRefGoogle Scholar
  11. 11.
    Bodinier M, Peyrat MA, Tournay C, Davodeau F, Romagne F, Bonneville M, Lang F (2000) Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding. Nat Med 6:707–710PubMedCrossRefGoogle Scholar
  12. 12.
    Labarriere N, Gervois N, Bonnin A, Bouquie R, Jotereau F, Lang F (2008) PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting. Cancer Immunol Immunother 57:185–195PubMedCrossRefGoogle Scholar
  13. 13.
    Gervois N, Heuze F, Diez E, Jotereau F (1990) Selective expansion of a specific anti-tumor CD8 + cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements. Eur J Immunol 20:825–831PubMedCrossRefGoogle Scholar
  14. 14.
    Jotereau F, Pandolfino MC, Boudart D, Diez E, Dreno B, Douillard JY, Muller JY (1991) LeMevel B (1991) High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy. J Immunother 10:405–411PubMedCrossRefGoogle Scholar
  15. 15.
    Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P (1998) Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 160:1750–1758PubMedGoogle Scholar
  16. 16.
    Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716–719PubMedCrossRefGoogle Scholar
  17. 17.
    Guilloux Y, Lucas S, Brichard VG, Van Pel A, Viret C, De Plaen E, Brasseur F, Lethe B, Jotereau F, Boon T (1996) A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med 183:1173–1183PubMedCrossRefGoogle Scholar
  18. 18.
    Vignard V, Lemercier B, Lim A, Pandolfino MC, Guilloux Y, Khammari A, Rabu C, Echasserieau K, Lang F, Gougeon ML, Dreno B, Jotereau F, Labarriere N (2005) Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells. J Immunol 175:4797–4805PubMedGoogle Scholar
  19. 19.
    Gervois N, Labarriere N, Le Guiner S, Pandolfino MC, Fonteneau JF, Guilloux Y, Diez E, Dreno B, Jotereau F (2000) High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells. Clin Cancer Res 6:1459–1467PubMedGoogle Scholar
  20. 20.
    Cole DJ, Wilson MC, Rivoltini L, Custer M, Nishimura MI (1997) T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Cancer Res 57:5320–5327PubMedGoogle Scholar
  21. 21.
    Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R (2006) Phase I study of adoptive T-cell therapy using antigen-specific CD8 + T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24:5060–5069PubMedCrossRefGoogle Scholar
  22. 22.
    Labarriere N, Bretaudeau L, Gervois N, Bodinier M, Bougras G, Diez E, Lang F, Gregoire M, Jotereau F (2002) Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen. Int J Cancer 101:280–286PubMedCrossRefGoogle Scholar
  23. 23.
    Yang S, Linette GP, Longerich S, Haluska FG (2002) Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209–2 M is correlated to TCR avidity. J Immunol 169:531–539PubMedGoogle Scholar
  24. 24.
    Cebecauer M, Guillaume P, Mark S, Michielin O, Boucheron N, Bezard M, Meyer BH, Segura JM, Vogel H, Luescher IF (2005) CD8 + cytotoxic T lymphocyte activation by soluble major histocompatibility complex-peptide dimers. J Biol Chem 280:23820–23828PubMedCrossRefGoogle Scholar
  25. 25.
    Freitag S, Le Trong I, Klumb L, Stayton PS, Stenkamp RE (1997) Structural studies of the streptavidin binding loop. Protein Sci 6:1157–1166PubMedCrossRefGoogle Scholar
  26. 26.
    Dutoit V, Rubio-Godoy V, Dietrich PY, Quiqueres AL, Schnuriger V, Rimoldi D, Lienard D, Speiser D, Guillaume P, Batard P, Cerottini JC, Romero P, Valmori D (2001) Heterogeneous T-cell response to MAGE-A10(254–262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res 61:5850–5856PubMedGoogle Scholar
  27. 27.
    Creagh EM, Conroy H, Martin SJ (2003) Caspase-activation pathways in apoptosis and immunity. Immunol Rev 193:10–21PubMedCrossRefGoogle Scholar
  28. 28.
    Peter ME, Krammer PH (2003) The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 10:26–35PubMedCrossRefGoogle Scholar
  29. 29.
    Gulow K, Kaminski M, Darvas K, Suss D, Li-Weber M, Krammer PH (2005) HIV-1 trans-activator of transcription substitutes for oxidative signaling in activation-induced T cell death. J Immunol 174:5249–5260PubMedGoogle Scholar
  30. 30.
    Knabel M, Franz TJ, Schiemann M, Wulf A, Villmow B, Schmidt B, Bernhard H, Wagner H, Busch DH (2002) Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 8:631–637PubMedCrossRefGoogle Scholar
  31. 31.
    Neudorfer J, Schmidt B, Huster KM, Anderl F, Schiemann M, Holzapfel G, Schmidt T, Germeroth L, Wagner H, Peschel C, Busch DH, Bernhard H (2007) Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Meth 320:119–131CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Régis Bouquié
    • 1
  • Annabelle Bonnin
    • 1
  • Karine Bernardeau
    • 1
  • Amir Khammari
    • 2
  • Brigitte Dréno
    • 1
    • 2
  • Francine Jotereau
    • 1
    • 3
  • Nathalie Labarrière
    • 1
  • François Lang
    • 1
    • 4
  1. 1.INSERM U892Nantes Cedex 1France
  2. 2.CHU of Nantes, Unit of Skin CancerNantesFrance
  3. 3.Faculté des SciencesUniversité de NantesNantesFrance
  4. 4.UFR des Sciences PharmaceutiquesUniversité de NantesNantesFrance

Personalised recommendations